123 related articles for article (PubMed ID: 20162550)
1. Alpha-GalCer ameliorates listeriosis by accelerating infiltration of Gr-1+ cells into the liver.
Emoto M; Emoto Y; Yoshizawa I; Kita E; Shimizu T; Hurwitz R; Brinkmann V; Kaufmann SH
Eur J Immunol; 2010 May; 40(5):1328-41. PubMed ID: 20162550
[TBL] [Abstract][Full Text] [Related]
2. Alpha-galactosylceramide promotes killing of Listeria monocytogenes within the macrophage phagosome through invariant NKT-cell activation.
Emoto M; Yoshida T; Fukuda T; Kawamura I; Mitsuyama M; Kita E; Hurwitz R; Kaufmann SH; Emoto Y
Infect Immun; 2010 Jun; 78(6):2667-76. PubMed ID: 20351146
[TBL] [Abstract][Full Text] [Related]
3. Deletion of C-C Motif Chemokine Ligand 5 Worsens Invariant Natural Killer T-Cell-Mediated Hepatitis via Compensatory Up-regulation of CXCR2-Related Chemokine Activity.
Chen L; Gu J; Qian Y; Li M; Qian Y; Xu M; Li J; Wen Y; Xia L; Li J; Xia Q; Kong X; Wu H
Cell Mol Gastroenterol Hepatol; 2019; 7(3):623-639. PubMed ID: 30630119
[TBL] [Abstract][Full Text] [Related]
4. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
[TBL] [Abstract][Full Text] [Related]
5. Role of γδ T cells in α-galactosylceramide-mediated immunity.
Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
[TBL] [Abstract][Full Text] [Related]
6. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.
Kitamura H; Iwakabe K; Yahata T; Nishimura S; Ohta A; Ohmi Y; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nishimura T
J Exp Med; 1999 Apr; 189(7):1121-8. PubMed ID: 10190903
[TBL] [Abstract][Full Text] [Related]
7. Preactivation of NKT cells with alpha-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor.
Cao Z; Yuan Y; Jeyabalan G; Du Q; Tsung A; Geller DA; Billiar TR
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G249-58. PubMed ID: 19556359
[TBL] [Abstract][Full Text] [Related]
8. α-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3.
Huang JR; Tsai YC; Chang YJ; Wu JC; Hung JT; Lin KH; Wong CH; Yu AL
J Immunol; 2014 Feb; 192(4):1972-81. PubMed ID: 24465013
[TBL] [Abstract][Full Text] [Related]
9. Pathogen-expanded CD11b+ invariant NKT cells feedback inhibit T cell proliferation via membrane-bound TGF-β1.
Han Y; Jiang Z; Chen Z; Gu Y; Liu Y; Zhang X; Cao X
J Autoimmun; 2015 Apr; 58():21-35. PubMed ID: 25592391
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant effects of invariant NKT cell ligand potentiates the innate and adaptive immunity to an inactivated H1N1 swine influenza virus vaccine in pigs.
Dwivedi V; Manickam C; Dhakal S; Binjawadagi B; Ouyang K; Hiremath J; Khatri M; Hague JG; Lee CW; Renukaradhya GJ
Vet Microbiol; 2016 Apr; 186():157-63. PubMed ID: 27016770
[TBL] [Abstract][Full Text] [Related]
11. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.
Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T
Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410
[TBL] [Abstract][Full Text] [Related]
12. An alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes.
Ly D; Tohn R; Rubin B; Blumenfeld H; Besra GS; Veerapen N; Porcelli SA; Delovitch TL
Clin Exp Immunol; 2010 May; 160(2):185-98. PubMed ID: 20015094
[TBL] [Abstract][Full Text] [Related]
13. Activation of Invariant Natural Killer T Cell Subsets in C57BL/6J Mice by Different Injection Modes of α-galactosylceramide.
Meng M; Chen S; Gao X; Liu H; Zhao H; Zhang J; Zhang J; Chen D
Iran J Allergy Asthma Immunol; 2020 Feb; 19(1):35-44. PubMed ID: 32245319
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activities of amino acids functionalized α-GalCer analogues.
Ma W; Bi J; Zhao C; Zhang Z; Liu T; Zhang G
Bioorg Med Chem; 2020 Jan; 28(1):115141. PubMed ID: 31786009
[TBL] [Abstract][Full Text] [Related]
15. Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis.
Stanley AC; Zhou Y; Amante FH; Randall LM; Haque A; Pellicci DG; Hill GR; Smyth MJ; Godfrey DI; Engwerda CR
PLoS Pathog; 2008 Feb; 4(2):e1000028. PubMed ID: 18463695
[TBL] [Abstract][Full Text] [Related]
16. Natural killer T cell ligand alpha-galactosylceramide protects against gut ischemia reperfusion-induced organ injury in mice.
Zhang J; Bi J; Ren Y; Du Z; Li T; Li Q; Ke M; Dong J; Lv Y; Wu R
Cytokine; 2018 Nov; 111():237-245. PubMed ID: 30195979
[TBL] [Abstract][Full Text] [Related]
17. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.
Nakagawa R; Nagafune I; Tazunoki Y; Ehara H; Tomura H; Iijima R; Motoki K; Kamishohara M; Seki S
J Immunol; 2001 Jun; 166(11):6578-84. PubMed ID: 11359810
[TBL] [Abstract][Full Text] [Related]
19. Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide.
Nakagawa R; Inui T; Nagafune I; Tazunoki Y; Motoki K; Yamauchi A; Hirashima M; Habu Y; Nakashima H; Seki S
J Immunol; 2004 Jun; 172(11):6550-7. PubMed ID: 15153469
[TBL] [Abstract][Full Text] [Related]
20. Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment.
Sasakawa A; Tatsumi T; Takehara T; Yamaguchi S; Yamamoto M; Ohkawa K; Miyagi T; Hayashi N
J Hepatol; 2009 Jun; 50(6):1155-62. PubMed ID: 19376606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]